News and Trends 6 Oct 2016 New UK Hero Will Fight Against Non-Small Cell Lung Cancer Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […] October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 A new Immuno-Oncology biotech’s Small Molecule hits the Clinic Since we interviewed Karus Therapeutics last year, the company has come quite a way! The Oxford-based biotech has just sent its first drug to the clinic. We first met Karus Therapeutics a year ago to talk about their small molecule therapies for cancer and inflammatory disease. The company has entered the immuno-oncology fray and is developing a […] October 6, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 €365M deal for a Danish ‘DNA barcode’ Drug Screening Platform The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 A Secretive new Oncology Biotech has made a Dramatic Debut Carrick Therapeutics has burst onto the oncology scene with a massive round of fundraising, reeling in almost €100M to become Europe’s cancer leader. Since its foundation last year, oncology upstart Carrick Therapeutics has mostly stayed off the radar. That changed yesterday, when it announced a splashy fundraising round of €85M ($95M) to propel it to the top of […] October 4, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Boehringer buys a €210M ticket to Virus-based Immuno-Oncology Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […] September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Titans in Gene Therapy and TCRs make a Massive Deal Medigene has licensed a few candidates from its TCR platform to one of the Boston ‘it’ biotechs in a deal totaling around €1B. By partnering with bluebird bio, Medigene is reestablishing itself as a leader in immuno-oncology. Founded over 20 years ago, Medigene has risen to the top of the European biotech scene with a […] September 29, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Debunking the Immuno-Oncology Hype: is it as good as it sounds? CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […] September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2016 Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […] September 28, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 SELLAS wants to sell us an Immunotherapy for Mesothelioma After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences. City: Zug (Zurich-area), Switzerland Founded: 2012 Employees: 11 – 50 Financial Data: None available…what a secretive cohort. Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on […] September 23, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2016 The Munich Biotech Mafia are at it again, raising €40M for an I/O Startup A new immuno-oncology startup has taken off with a booming round of VC fundraising. Details on its programs are sparse, but the company’s leadership is a veritable who’s who in German biotech, much like the PayPal Mafia. Immuno-oncology is surely an exciting field, but high-profile leadership is a huge bonus when it comes to attracting […] September 23, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 A new player has entered the Game: €29M for DDR Cancer Therapy Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […] September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016 German Biotech allies with Genentech in battle for Cancer Vaccine BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […] September 21, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email